Liquid Biopsy for Precision Oncology Summit West Coast leaderboard
  • Friday, November 20, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

SmartLab Exchange Europe 2027 Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Page 9

Johnson & Johnson’s Tremfya Shows Crohn’s Disease Benefits Through Three Years

Oct 14, 2026
Johnson & Johnson has announced three-year clinical data showing that Tremfya (guselkumab) maintained clinical and endoscopic remission in adults with moderately to severely active…
Read More...

Enodia Therapeutics and Pfizer Sign Deal Worth Over $500 Million

Oct 14, 2026
Enodia Therapeutics has entered into a research collaboration and licensing agreement with Pfizer to discover and develop small-molecule drugs targeting Sec61, a protein channel…
Read More...

Charles River Partners with Magellan to Advance Stem Cell Therapy

Oct 14, 2026
Charles River Laboratories has partnered with Australian biotechnology company Magellan Stem Cells to support the development and clinical advancement of its stem cell therapies,…
Read More...

Zealand Pharma and Generate Biomedicines Partner on AI-Designed Obesity Treatments

Oct 14, 2026
Zealand Pharma and Generate Biomedicines have announced a strategic collaboration to develop AI-designed protein therapies for obesity and other metabolic diseases. The partnership will…
Read More...

Teva Wins FDA Approval for Once-Monthly Schizophrenia Injection

Oct 12, 2026
Teva Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for WELTRUZA (olanzapine), a once-monthly injectable treatment for adults with schizophrenia.…
Read More...

Roche Reports One-Year Benefits for Vamikibart in Eye Disease

Oct 12, 2026
Roche has announced positive one-year results from two Phase 3 clinical trials evaluating its investigational drug vamikibart for uveitic macular edema (UME), a serious eye condition…
Read More...

Roche Wins FDA Approval for Tecentriq in Stage III Colon Cancer

Oct 12, 2026
Roche has received approval from the US Food and Drug Administration (FDA) for Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), in combination with…
Read More...

Cognizant Extends Gilead Partnership to Expand AI-Enabled DevOps

Oct 7, 2026
Cognizant has extended its partnership with Gilead Sciences for five years to support the biopharmaceutical company’s technology programs, with a focus on DevOps and the responsible use…
Read More...

CSL, Alentis Partner on $1.55B Kidney and Liver Drug

Oct 7, 2026
CSL and Alentis Therapeutics have entered into an exclusive global collaboration to jointly develop and commercialize lixudebart, an investigational treatment that targets claudin-1 for…
Read More...

Alector Licenses Parkinson’s Drug Program to Genentech for $1.27B

Oct 7, 2026
Alector has entered into an exclusive global licensing agreement with Genentech, a member of the Roche Group, to develop and commercialize AL050, an investigational therapy designed to…
Read More...
Previous 1 … 7 8 9 10 11 … 966 Next
Oligonucleotide-based Therapeutics Summit
LEAP HR: Life Sciences Europe
3rd Annual TRP Target Selection & Drug Design Summit
2nd Structure-Based Drug Design Summit San Diego
Liquid Biopsy for Precision Oncology Summit West Coast
2nd Non-Opioid Pain Therapeutics Summit
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Antigen-Specific Immune Tolerance Summit
7th Operationalize Expanded Access Programs Summit
Viral Vector Process Development & Manufacturing Summit
SmartLab Exchange Europe 2027
8th RNAi-Based Therapeutics Summit
17th World ADC London
PFS & Injectable Drug Devices Europe
Ophthalmic Drug Delivery Summit
Obesity & Weight Loss Drug Development Summit West
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Biomarker Operations & Biospecimen Management
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • OBI Pharma Signs $2 Billion ADC Deal with Novartis
  • Erasca and Bristol Myers Squibb Partner on Pancreatic Cancer Treatment
  • GSK Wins FDA Approval for Nelkarmi in Advanced Lung Cancer
  • OXB Partners with Aura Biosciences for Phase 3 Cancer Drug Development
  • Skylark Bio Advances Hearing Loss Gene Therapy to Younger Children

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Cell Therapy Safety in Autoimmune Disease

7th Operationalize: Expanded Access Programs Summit East…

As AI and ICH M15 Transform Drug Development, Industry…

Industry Leaders Explore the Future of RNA Therapeutics…

Direct RNA Binding Emerges as a Powerful Approach for…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.